On the stock market since 2021, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $87.1M a year. A small number, but proof the product has real buyers.
A loss of $8.0M against $87.1M in annual sales.
Over the last 12 months, executives reported 6 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, VENAU sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VENAU is a high-risk stock — not yet profitable, and its future rides on its product catching on.